Views & Analysis Innovative contracting in Europe: a Trojan Horse? By Mary Iyiola & Agnieszka Janska, with additional consultation by Smita Sealey & Barry Farrimond
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
